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AbstrAct
Introduction Psychosocial factors are increasingly 
recognised as important determinants of cardiovascular 
disease risk. The North Texas Heart Study aims to 
understand the mechanisms responsible for this 
association with a focus on social vigilance (ie, scanning 
the environment for social threats). There is also growing 
interest in supplementing traditional methods (eg, survey 
assessment of psychosocial risk paired with cross-
sectional and longitudinal health outcomes) with daily or 
repeated momentary assessment of psychosocial factors. 
However, there are relatively few longitudinal studies 
directly comparing these approaches with hard endpoints.
Methods and analysis The North Texas Heart Study 
proposes a longitudinal measurement burst design 
to examine psychosocial determinants of subclinical 
atherosclerosis. A sample of 300 healthy community 
participants, stratified by age and gender, will complete 
survey measures, as well as 2 days of ecological 
momentary assessment at baseline and at a 2-year 
follow-up. A range of psychosocial and behavioural factors, 
objective biomarkers, as well as carotid intima-media 
thickness (cIMT) will be assessed at both time points. 
Unadjusted and adjusted models will evaluate cross-
sectional associations and determinants of change in the 
cIMT.
Ethics and dissemination The Institutional Review 
Board at the study coordinating institute (University of 
North Texas) has approved this study. Positive, negative 
or inconclusive primary and ancillary findings will be 
disseminated in scientific journals and conferences.
IntroductIon
Substantial evidence supports psychosocial 
stress as an important risk factor for the 
development of cardiovascular disease (CVD) 
morbidity and mortality, as well as all-cause 
mortality.1–7 For example, more frequent 
exposure to social stress, including interper-
sonal conflict, discrimination, hostile work 
environments and disadvantaged neighbour-
hoods increase the risk for coronary heart 
disease (CHD) morbidity and mortality.8–14 
Individual differences in the tendency to 
perceive or experience social stress as more 
severe has also been prospectively associated 
with accelerated atherosclerotic progression, 
adverse cardiac events and mortality.15–19
Vigilance reflects a sensory intake process20 
where an environment or potential threat is 
continually monitored and reappraised in 
order to detect any change in status. Social 
vigilance is one behaviour that could poten-
tially link stress and a broad array of individual, 
social and contextual moderators to CVD (see 
figure 1). Social vigilance refers to the act of 
monitoring the social environment for poten-
tial interpersonal challenges or threats, as well 
as monitoring change in status of a perceived 
threat.21 22 This behaviour may be automatic, 
as in general surveillance, or effortful when 
monitoring a specific target or environment. 
Notably, several factors may evoke more 
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Protocol
strengths and limitations of this study
 ► This study is significant in that it evaluates social 
vigilance as a novel though ecologically valid 
behavioural risk factor for stress-related disease.
 ► The mixed methods longitudinal design facilitates 
both a broad relationship understanding of social 
vigilance and its relationship to atherosclerotic 
disease as well as daily biobehavioural interactions 
that may mediate disease progression.
 ► The multimethod assessment of social vigilance 
including use of the same measure in traditional 
survey, daily diary and momentary assessment 
formats will allow comparison of granularity 
differences in association with outcomes.
 ► Despite our best efforts, it is possible that either 
the amount of measureable disease will be too low 
to detect in our healthy sample or that insufficient 
change will occur within the 2-year follow-up to 
ascertain vigilance effects on progression.
 ► It is also possible that despite conceptual distinctions, 
social vigilance simply does not translate into unique 
disease impact.
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Figure 1 Conceptual model illustrating the role of social vigilance. Path A demonstrates the broad relationship between 
psychosocial stress and atherosclerotic disease. Paths B and C represent the hypothesised mediational role of social vigilance. 
Path D represents the acute physiological concomitants of socially vigilant behaviour. Path E represents the direct physiological 
pathway to disease as a function of chronicity. BP, blood pressure; cIMT, carotid intima-media thickness.
chronic vigilance of the social environment and may 
include individual differences (eg, hostility and negative 
affectivity), more challenging social environments (eg, 
unsafe neighbourhoods and hostile work environments) 
and social roles requiring vigilant observation (eg, secu-
rity work and caregiving). Although social vigilance may 
be adaptive in some contexts (eg, dangerous situations), 
sustained vigilance or hypervigilance may have important 
health consequences.
Prior evidence suggests that vigilant behavior evokes a 
pattern of vascular resistance characterized by increases 
in blood pressure (BP) and total peripheral resistance 
(TPR), often with little change in heart rate (HR). 23 24 
Such patterns may represent a significant risk factor for 
CVD.19 25 This finding is supported by a number of tradi-
tional tasks that aim to evoke vigilant behaviour, including 
mirror tracing,26–28 the Stroop colour-word interference 
task26 29 and computerised signal detection tasks.30 Addi-
tional evidence from our lab broadens these findings 
to vigilance of social stimuli.24 For example, men that 
viewed a video of a potential competitor exhibited larger 
increases in both BP and TPR compared with those who 
monitored a non-competitive social target. Together, this 
research supports a mediating pathway linking psycho-
logical stress to increased physical disease risk through 
increased vascular resistance.
Experience sampling, or ecological momentary 
assessment (EMA), is a research method used to assess 
psychosocial factors in temporal proximity to their 
experience with the inference that this approach improves 
the ecological validity of the experience relative to more 
traditional survey recall efforts. It is superior to tradi-
tional self-report measures for assessing the frequency, 
nature and content of acute experiences as it samples in 
real time and in naturalistic settings.31–33 This method, 
in combination with assessment of emotional, psycho-
physiological and biological processes in real time, may 
provide important information regarding the contexts 
that increase risk and potentially reveal mechanisms 
that may underlie physical change. For example, a series 
of research studies by Kamarck and colleagues demon-
strated that daily task demands were cross-sectionally 
associated with carotid intima-media thickness (IMT)34 
and longitudinally predictive of disease progression, with 
additional evidence suggesting potential mediation by 
baseline ambulatory BP.35 The application of this evolving 
real-time microprocess assessment methodology should 
help to improve our understanding of how concepts like 
vigilance are experienced in everyday life to influence 
disease risk and progression.
AIMs
The North Texas Heart Study is a longitudinal investi-
gation that will examine the impact of social vigilance 
and daily experiences on the development of subclinical 
atherosclerosis. The first aim of this study is to examine 
social vigilance as a predictor of progression of carotid 
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Figure 2 The North Texas Heart Study protocol. BP, blood 
pressure; EMA, ecological momentary assessment.
IMT in an initially healthy community sample. Second, 
this study aims to examine whether ambulatory BP medi-
ates the relationship between social vigilance and carotid 
IMT. To help elucidate the mechanisms that underlie 
or serve to promote atherosclerotic progression, an 
exploratory aim of this study is to capture measures of 
psychosocial well-being, health behaviours, emotional 
responses, subjective and objective sleep quantity and 
quality, and inflammatory biomarkers at study intake and 
again at a 2-year follow-up. It is hypothesised that greater 
social vigilance will be associated with higher carotid IMT 
values at each time point, as well as predict carotid IMT 
progression over time. We also expect that daily BP 
responses to momentary social vigilance will mediate the 
effects of vigilance on carotid IMT progression at 2-year 
follow-up. Findings from this study will help to elucidate 
the behaviourally manifested CVD risk factors, which can 
then serve as intervention targets to reduce CVD risk.
MEthods And AnAlysIs
Project overview
This longitudinal investigation proposes to evaluate social 
vigilance as a cognitive, behavioural and emotional risk 
factor for higher levels of atherosclerosis in a racially 
and economically diverse sample recruited from Denton 
County, Texas, USA. The study will employ multiple 
methods for data collection including self-report surveys, 
daily experience assessments, ambulatory monitoring, 
medical examinations, imaging and biomarker analysis. 
Data collection will take place at study entry and again 
at a 2-year follow-up. This multimethod approach will 
provide rich data affording the opportunity to examine 
psychosocial contributions to objective disease progres-
sion and contrast the predictive value of variations in 
sampling from survey to momentary experiences.
Participants and recruitment
A baseline community sample of 300 adults (150 men and 
150 women), ages 21–70 years will be recruited from 
Denton County, Texas. The sample will be stratified by 
age (by decades) within gender and race/ethnicity in 
order to examine age-related effects. Participants will 
be recruited through a variety of sources including, but 
not limited to, advertisements in local newspapers, flyers, 
community and university websites, hospital postings and 
community organisation postings.
Denton County is an economically and racially diverse 
community located approximately 30 miles north of 
Dallas. The Denton County population was estimated 
to be 658 616 persons in 2009 with a racial make-up 
described as 83.3% white, 8.3% black and 5.7% Asian. 
In addition, 17.9% of the community is of Hispanic/
Latino ethnicity including a sizeable immigrant popula-
tion. The current study will aim to oversample Hispanic/
Latinos and non-Hispanic blacks to achieve at least 25% 
Hispanic/Latinos and 15% non-Hispanic black/African 
Americans with approximately 54.5% non-Hispanic white 
and 5.5% non-Hispanic Asian. To achieve our racial/
ethnic minority representation goals, we will partner 
with neighbourhood/community leaders to promote the 
study aims and benefits to participants. Consistent with 
this effort, we will also use promotores de salud (Hispanic/
Latino community health workers, patient navigators or 
healthcare advocates) to bolster recruitment of Hispanic/
Latino participants. Given that promotores come from the 
communities they aim to serve, they represent a unique 
cultural and linguistic pathway that may also facilitate 
recruitment for research.
To be eligible, participants must be: (1) over 21 years 
of age, (2) residing within Denton County and (3) have 
written and verbal fluency in English language. Exclusion 
criteria are: (1) cognitive impairment (ie, dementia), 
(2) previous history of myocardial infarction or tertiary 
cardiac interventions (eg, coronary artery bypass 
surgery and implanted cardiac defibrillator), (3) preg-
nancy within last year or anticipating pregnancy during 
study period and (4) an occupation that requires shift 
work. Screening will be conducted to verify no evidence 
of manifest cardiac disease. The use of anti-inflammatory 
and lipid management medications will be assessed as 
covariates but will not be a cause for exclusion.
Procedure
The study protocol is outlined in figure 2. The study will 
be coordinated by a research team at the University of 
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North Texas. All laboratory visits will be conducted at a 
single vascular medicine clinic located in the community.
Screening and consent
Potential participants will be screened for eligibility 
by the study coordinator via phone. A target matrix of 
gender, age by decade and race/ethnicity will be used 
to ensure the sampling goals: equal gender and racial/
ethnic representation within each decade from 21 to 70 
years at time of enrolment. Participants that meet recruit-
ment targets, as well as inclusion/exclusion criteria, will 
be scheduled for a session.
All sessions will take place on Thursday mornings 
between the hours of 08:00 and 10:00. Participants will be 
instructed to fast overnight (8 hours). This constrained 
appointment time (all participants run in the same 2- to 
3-hour morning block) is important to ensure the fidelity 
of inflammatory biomarkers.36 Participants will meet the 
study coordinator at the clinic at their scheduled appoint-
ment time to provide written, informed consent and 
begin the protocol.
Laboratory visit
After consent is provided, participants will undergo a 
brief physical exam that includes a review of systems 
(ROS), personal and family medical history, current 
medications and health conditions, health behaviours 
and detailed cardiac disease history. A fasting blood 
draw to assess lipids and inflammatory markers will be 
performed. A vascular technologist will then perform 
a complete bilateral ultrasound imaging study of the 
extracranial carotid arteries and related vasculature. 
Finally, participants will complete a questionnaire 
package that includes measures of vigilance, social 
experiences, personality and health behaviours. Prior to 
leaving the laboratory, all participants will be fitted with 
a wrist-worn Actiwatch Spectrum (Phillips-Respironics) 
sleep/wake activity monitor, an ambulatory blood pres-
sure monitor (ABPM; Oscar II; Suntech), and will be 
given a preprogrammed mobile device for a 2-day/2-
night ambulatory/EMA assessment.
Ambulatory/EMA assessment
ABPM measurements will be programmed to assess BP at 
random times within 45 min intervals throughout the day. 
This random sampling procedure prevents participants 
from anticipating a measurement and hence altering 
their activities. Participants will be instructed to complete 
the EMA protocol using the provided mobile device in 
response to each BP measurement during awake hours. 
Participants will be further instructed to complete two 
additional EMA-based surveys: (1) an End-of-Day (EOD) 
Survey completed at bedtime and (2) a morning survey 
on awakening (ie, Wake Survey). The Actiwatch Spectrum 
will be programmed to assess activity at 30 s epochs, and 
participants will be instructed to leave the watch on for 
the entire 2-day/2-night monitoring period. Participants 
will be instructed to turn off the ABPM and remove it at 
bedtime on the first night and to attach and activate it on 
awakening the next morning. On the second night, partic-
ipants will wear the ABPM in order to collect nocturnal 
BP data (eg, in order to estimate nocturnal dipping). On 
the third day, participants will meet the study coordinator 
at the clinic to return the ambulatory/EMA equipment. 
Participants will also be asked about the development of 
acute illness symptoms since the previous appointment as 
a means to account for potential prodromal illness states 
(ie, asymptomatic states of infection) on inflammation 
markers.
Longitudinal assessment
Longitudinal change on all measures will be evaluated by 
repeating the protocol at a 2-year follow-up visit using the 
same procedure outlined above. Specifically, participants 
will repeat the medical exam, questionnaire package, 
fasting blood draw, ultrasound scan and 2-day/2-night 
ambulatory/EMA protocol. A follow-up period of 2 years 
was deemed an appropriate follow-up length based 
on previous research that demonstrated the impact of 
psychosocial risk factors on change in carotid IMT over 
this time period.37–40
Measures
Three types of measures will be collected: (1) psychoso-
cial survey data (table 1), (2) ecological sampling data 
including both EMA and daily diaries (table 2) and 
(3) ambulatory physiological and clinical outcomes 
data (table 3). Below we detail specific domains and 
constructs.
Demographics
Demographic data including age, race, ethnicity, house-
hold income, education attainment, marital status, 
household size, occupational status (Hollingshead classi-
fication),41 42 typical work hours and military experience 
will be assessed through self-report. These variables will 
be used as covariates in models testing the first aim and 
may also serve ancillary purposes at a later time.
Psychosocial well-being and health behaviours
A self-report questionnaire package will be used to collect 
four domains of conceptually relevant psychosocial risk 
moderators (see table 1 for additional detail). Domains 
include: (1) individual-level factors including health 
behaviours, mood/affect and personality traits, (2) 
social factors, (3) social roles and (4) contextual factors. 
Measures were chosen based on four criteria: (1) rele-
vance to the vigilance construct, (2) relevance to disease 
risk, (3) psychometric properties and (4) length.
Social vigilance
Social vigilance will be assessed with a new instrument—
the Social Vigilance Questionnaire (SVQ). The SVQ 
is a newly developed 10-item, three-factor self-report 
measure assessing the degree to which a person engages 
in stress-related vigilance or monitoring of the social envi-
ronment. Participants will be provided the stem, ‘In social 
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Table 1 Domains, constructs and measures in the psychosocial survey
Domain Construct Measure Description
Health behaviours
Physical activity Global Physical Activity 
Questionnaire71
Assesses physical activity at work, during transportation 
and during leisure; used to calculate metabolic equivalents
Smoking Tobacco use* Assesses current and past smoking and nicotine use 
behaviour
Alcohol use Alcohol Use Questionnaire* Assesses current and past alcohol use, including frequency 
and amount
Sleep Insomnia Severity Index72 Assesses the perceived severity of DSM-V chronic 
insomnia symptoms
Snoring, Tired, Observed, 
Blood Pressure73
Assesses self-reported symptoms of sleep apnoea; 
score ≥2 indicative of apnoea risk
Self-Assessment of Sleep* Assesses sleep quantity and quality during the week and 
weekends, number of hours needed to feel rested, overall 
sleep quality and duration of current sleep pattern
Psychosocial stress
Social vigilance Social Vigilance Questionnaire 
(SVQ)*
Assesses frequency of vigilant behaviours in social 
contexts; subscales include: social threats, others’ 
reactions to self, self
Perceived stress Perceived Stress Scale74 Assesses perceptions of the frequency of stressful events
Job strain Job Content Questionnaire75 Assesses psychological dimensions of job environments; 
subscales include: job demand, job control, job strain
Individual differences
Trait negative 
affect
Eysenck Personality 
Questionnaire – Neuroticism76
Assesses trait negative affectivity
Trait anger/
hostility
Aggression Questionnaire77 Assesses trait anger and hostility (subscales only)
Trait optimism Life Orientation Test-Revised78 Assesses dispositional optimism/positivity and 
dispositional pessimism
Trait anxiety State Trait Anxiety Inventory79 Assesses individual differences in dispositional anxiety
Depressive 
symptoms
Center for Epidemiological 
Studies- Depression Scale80
Assesses depressive symptoms and levels of depression
Cognitive 
rumination
White Bears Suppression 
Inventory81
Assesses tendency to suppress thoughts
Social functioning
Perceived social 
support
Interpersonal Support 
Evaluation List 82
Assesses perceived social support; subscales include: 
appraisal, belonging, tangible
Perceived 
discrimination
The Everyday Discrimination 
Scale (EF)83
Assesses frequency of perceived unfairness and 
attributions for such treatment (eg, race/ethnicity, age, 
gender and so on)
Relationship 
distress
Marital Satisfaction 
Inventory84 85
Assesses degree of marital distress; subscales include: 
disaffection, disharmony
Relationship 
ambivalence
Social Relationships Index86 Assesses positive and negative dimensions of 
interpersonal relationships
DSM-V, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition 
* measure developed for this study
situations…’ followed by the items that are rated using a 
4-point Likert scale ranging from 0 ‘almost never’ to 4 
‘almost always’.
We propose to assess the frequency of socially vigi-
lant behaviour using the SVQ with two conceptually 
related but distinct methodologies. First, the SVQ will be 
included in the self-report questionnaire package that all 
participants complete at baseline. The second approach 
will be to assess the frequency of vigilant behaviour in 
daily life using EMA sampling. The full 10-item SVQ will 
be adapted to the EMA format by altering the stem to 
sample vigilant behaviour ‘since the last reading’ and will 
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Table 2 Constructs and items assessed using EMA Cuff Survey, End-of-Day Survey and Wake Survey
Assessment Construct Description
EMA Cuff-Survey Physical attributes Seven items assessing physical covariates at cuff inflation:
Posture
Activity level
Talking during measurement
Temperature
Location
Recent consumption of food, alcohol, nicotine
Recent exercise
Affect 12 items (1 ‘not at all’ to 7 ‘extremely’):
Energetic (lively and energetic)
Relaxed (relaxed and calm)
Anxious (nervous and tense)
Sad (sad and depressed)
Positive (cheerful and happy)
Hostile (hostile and angry)
Stress Three items assessing:
Stressful event since prior measure (yes/no)
Stressor severity (1 ‘not at all’ to 7 ‘extremely’)
General stress levels since previous inflation
(1 ‘not at all’ to 7 ‘extremely’)
Social exposure One item assessing social exposure (yes/no)
Social vigilance If social exposure=yes:
10-item Social Vigilance Questionnaire (SVQ)
Social isolation If social exposure=no:
10 items assessing social isolation
Interpersonal exposure One item assessing interactions (yes/no)
Interpersonal interactions If interpersonal exposure=yes, three items assessing:
Identify the relationship (who was interaction with)
Rate the positive quality (1 ‘not at all’ to 7 ‘extremely’)
Rate the negative quality (1 ‘not at all’ to 7 ‘extremely’)
If interpersonal exposure=no, three items assessing:
Reason for no interaction (eg, no opportunities and avoiding)
Likelihood of avoiding an interaction by the next cuff inflation
(1 ‘not at all’ to 7 ‘extremely’)
Likelihood of initiating an interaction by the next cuff inflation
(1 ‘not at all’ to 7 ‘extremely’)
State optimism Two items assessing positive and negative outlook in next 30 min
(1 ‘strongly disagree’ to 7 ‘strongly agree’)
End-of-Day Survey Daily summary of affect, stress, 
social vigilance
Stem - ‘In general today…’
12 items assessing affect (1 ‘not at all’ to 7 ‘extremely’):
Energetic (lively and energetic)
Relaxed (relaxed and calm)
Anxious (nervous and tense)
Sad (sad and depressed)
Positive (cheerful and happy)
Hostile (hostile and angry)
Two items assessing stress:
How stressed did you feel today (1 ‘not at all’ to 7 ‘extremely’)
How did stress compare to typical day (1 ‘much more’ to 7 ‘far below’)
10-item SVQ
Wake Survey Self-reported sleep Eight items assessing previous night’s sleep to obtain measures of:
Time in bed
Sleep onset latency
Number of awakenings
Wake after sleep onset
Terminal wakefulness
Total sleep time
Sleep efficiency
Use of sleep medications
Sleep quality
EMA, ecological momentary assessment.
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Table 3 Ambulatory physiological and clinical outcomes
Assessment Construct Description
Ambulatory blood 
pressure (ABP)
Blood pressure Oscillometric data capture of blood pressure at random intervals within 
45 min blocks over 2 days and 1 night to obtain measures of:
Systolic blood pressure
Diastolic blood pressure
Mean arterial stiffness
Heart rate
Actigraphy Objective sleep Passive data capture of movement using wrist actigraphy over two nights to 
obtain measures of the following constructs:
Time in bed
Sleep onset latency
Number of awakenings
Wake after sleep onset
Terminal wakefulness
Total sleep time
Sleep efficiency
Use of sleep medications
Sleep quality
Fasting blood draws Metabolic Fasting blood glucose
Lipids Low-density lipoprotein
High-density lipoprotein
Triglycerides
Total cholesterol
Inflammation High-sensitivity C-reactive protein
Tumour necrosis factor-alpha
Interleukin-6
B-Mode ultrasound Carotid artery imaging Bilateral assessment of the carotid vasculature using standard angles (90°, 
150°, 210°, 270°) to obtain the following derived measures:
Mean max far common carotid artery
Mean max bifurcation (BIF)
Mean max internal carotid artery (ICA)
Mean max combined BIF/ICA
be assessed at each BP measurement if a social interac-
tion has taken place. This method will allow for a dynamic 
measure of vigilant behaviour at ~45 min intervals during 
the day.
Medical history and exam
At the laboratory session, a registered nurse will meet 
with participants to document health at study initiation 
and describe their personal and family health history. 
The physical exam includes assessment of standard 
anthropomorphic measures (eg, height, weight, waist 
circumference and so on), health behaviour informa-
tion (eg, smoking, alcohol use, physical activity, diet and 
sleep) and an ROS (eg, functioning and symptoms in 
all major regulatory system including but not limited to 
cardiovascular, respiratory, ears, nose, mouth, throat, 
gastrointestinal and so on). Three measures of resting BP 
will be collected and aggregated as a baseline measure 
of clinic BP. A phlebotomist will perform a fasting blood 
draw to assess a baseline lipid profile (ie, total cholesterol, 
high-density lipoprotein, low-density lipoprotein and 
triglycerides), fasting glucose, and to collect serum to 
assess inflammatory markers.
Carotid imaging
The extracranial carotid arteries will be imaged using 
B-mode ultrasound. The approach yields a two-dimen-
sional (2D) image of the carotid vasculature enabling 
measurement of wall thickness. Advances in ultrasound 
imaging using Doppler allow for measuring and visualising 
blood flow velocity. For the current study, all participants 
will undergo a carotid artery duplex scan. The term ‘duplex’ 
refers to the combination of B-mode with Doppler, which 
creates a 2D image with blood flow. This approach allows 
for traditional carotid IMT measurement, as well as infor-
mation on blood flow direction, flow velocities, occlusive 
disease, significant plaque and other abnormalities.43 44
All scans will be performed by experienced sonog-
raphers. Briefly, Dicom images will be captured for the 
common (CCA), bifurcation (BIF) and the internal 
carotid artery (ICA) segments interrogated from four 
standard angles (90°, 150°, 210° and 270°). Consistent 
with recommendations,45–47 a Meijer’s Carotid Arc (Meijer 
Medical Ultrasound; Voorschoten, The Netherlands) will 
be used to improve the precision of measurement points 
and to improve reliability of within-participant measure-
ment over time.
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Using Vascular Research Tools, V.5.0 (Medical Imaging 
Applications, Coralville, Iowa, USA), two readers blinded 
to the characteristics of the participants will score the 
carotid IMT offline. This software uses a semiautomated 
edge detection algorithm to ascertain the thickness of the 
intima-media complex in the designated region of interest 
(ROI) for each frame in the series of the clip. Consistent 
with the literature, carotid IMT is defined as the distance 
between the intimal-luminal and the medial-adventitial 
interfaces of the arterial segment within the ROI. Each 
segment will also be analysed for the presence or absence 
of plaques. Plaques will be given a quality score using the 
following criteria: (1) size (ie, small, medium and large), 
(2) heterogeneity/homogeneity and (3) fibrous, fatty and 
calcified. The software generates average, minimum and 
maximum IMT scores for each segment at each angle. 
The maximum IMT value will be used as the marker of 
focus in accordance with prior recommendations48 and 
the team’s past work.49 50 Mean of the maximums (mean 
of the maximum scores for each of the four angels for a 
given segment) will be derived for the CCA, BIF and ICA.
Inflammatory biomarkers
To examine inflammation, as it pertains to potential 
effects of social vigilance on atherosclerosis, we will 
assess high sensitivity C-reactive protein (CRP), tumour 
necrosis factor-alpha (TNF-α) and interleukin 6 (IL-6). 
These markers are hypothesised to represent different 
points along the inflammatory process from stress to 
atherosclerosis, and their inclusion allows us to address 
not only presence of inflammation but also address how 
active inflammatory processes may influence all phases of 
the atherosclerotic processes.51–53 CRP has received the 
greatest attention as a marker of inflammatory processes 
and is a robust predictor of future cardiovascular risk 
in a number of prospective studies.54–58 However, CRP 
is a relatively late step in the inflammatory process and 
understanding earlier cytokine patterns that precede it 
and initiate the inflammatory cascade is important for 
theoretical models linking psychosocial factors relation-
ships to health outcomes. To this point, TNF-α is generally 
conceptualised as an acute phase cytokine and IL-6 is 
conceptualised as a central early inflammatory cytokine 
that can directly initiate and modulate the inflammatory 
cascade.59 60
Ambulatory BP
Participants will be fitted with an ABPM (Oscar 2; 
Suntech Medical Instruments, Raleigh, North Carolina) 
to wear during the day and evening to capture measures 
of systolic blood pressure, diastolic blood pressure and 
HR. The Oscar 2 was designed specifically for ambulatory 
assessments and is the only ABPM clinically validated to 
all three international standards.61 62 The sensors and 
the cuff are unobtrusively worn under the participants’ 
clothing, and only a small control unit (approximately 
4.7×2.8×1.2 inches; 284 g) attached to the participant’s 
belt is partially exposed. The ABPM will be programmed 
to assess BP at random times during 45 min intervals 
during the first and second study days and the second 
study night (2 days, 1 night). Data will be cleaned using 
established criteria.63 Participants will be trained how to 
remove and put back on the unit after bathing or vigorous 
exercise but otherwise will be asked to keep the monitor 
on as instructed.
Ecological momentary assessment
Participants will be provided with a preprogrammed 
mobile device that serves as the EMA delivery platform. 
Daily experiences will be assessed using three surveys: (1) 
the EMA/Cuff Survey, which serves as the primary momen-
tary sampling survey throughout the study day, (2) the 
EOD Survey to assess participant’s summary impressions 
of their day and (3) the Wake Survey, which will take the 
form of a sleep diary by assessing aspects of sleep quantity 
and quality (table 2). Programming includes drop down 
menus and slide bars for Likert scales.
The EMA/Cuff Survey
The EMA/Cuff Survey will serve as the primary daily 
sampling survey and will be paired with ABPM, where 
the BP sampling will serve as the triggering event for 
the participant to complete the survey. The EMA/Cuff 
Survey is divided into six measurement sections: physical 
parameters, affect, stress, social exposure, interpersonal 
interactions and perceived outlook (see table 2 for addi-
tional detail). Importantly, this survey is balanced such 
that participants receive relatively equal numbers of ques-
tions (range 38–40 questions) regardless of responses. 
This reduces the likelihood of inadvertently entraining 
certain answers that are associated with shorter survey 
requirements.
EOD Survey
Participants will be instructed to complete the EOD 
Survey at bedtime on the first and second days. The 
purpose is to assess summary ratings of: affect, stress and 
vigilance during that day.
The Wake Survey
Participants will be instructed to complete the Wake 
Survey when they wake on the second and third study 
days. The Wake Survey is a retrospective sleep diary64 
that assesses aspects of the previous night’s sleep. It is 
comprised of items that will provide measures of: sleep 
onset latency, time in bed, number of awakenings, wake 
after sleep onset, terminal wakefulness, total sleep time, 
sleep efficiency, sleep quality and use of sleep medication.
Sleep assessment
Subjective sleep quantity and quality
Participant sleep quantity and quality will be assessed 
during each laboratory visit using three self-report 
measures (table 1). Overall, these measures are designed 
to measure: (1) self-reported sleep duration and quality, 
(2) subjective insomnia symptom severity and (3) self-re-
ported sleep apnoea risk.
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Objective sleep quantity and quality
The Actiwatch Spectrum Actiwatches (Philips-Respironics, 
Bend, Oregon) are compact, wrist-worn, battery-operated 
activity monitors with physical characteristics similar to 
a small wristwatch. The monitor utilises a motion sensor 
known as an ‘accelerometer’ to monitor the occurrence 
and degree of motion. This type of sensor integrates the 
degree and speed of motion and produces a small signal 
where magnitude and duration depend on the amount 
of motion. Activity data will be collected over 30 s epochs. 
In addition, Actiwatch Spectrum has an on-board event 
marker button that the patient presses to identify bedtime 
and out of bed times. This information is analysed with 
Actiware (Philips-Respironics) software using settings of 
medium activity threshold and 10 immobile minutes to 
detect wakefulness. Derived variables include: bedtime, 
wake time, time in bed, sleep onset latency, number of 
awakenings during the night, wake time after sleep onset, 
total sleep time and sleep efficiency, using proprietary 
scoring algorithms in the software. Actigraphy and sleep 
diary/EMA data will be combined to optimise assessment 
of sleep parameters.
sample size and power analysis
Sample size and power were estimated from previous 
research examining conceptually relevant individual 
difference measures and carotid IMT. These data 
suggest effect sizes were comparable across a range 
of trait negative affects including hostility, anger and 
anxiety.38 40 65 66 Assuming that the correlation between 
the change in social vigilance score and the change in 
carotid IMT is at least 0.20, a total of 210 subjects who 
complete baseline and follow-up will yield 83% power 
to detect 20% correlation against the null hypothesis of 
no correlation using a two-sided test with a significance 
level of 0.05. Borrowing from Stewart and colleagues,38 
power is boosted to 90% if we assume that there is an 
increasing trend in carotid IMT over tertiles of social vigi-
lance assuming that a common SD within each tertile is 
0.10. Finally, in Stewart and colleagues38 study, 360 out of 
464 enrolled subjects completed baseline and follow-up 
assessments of carotid IMT. Assuming a similar comple-
tion rate (ie, 78%), we need to recruit a total of 270 
subjects to account for dropout. Hence, our targeted 
sample of 300 participants should be sufficient to detect 
the hypothesised relationships accounting for progres-
sion rate, strength of association and attrition.
EthIcs And dIssEMInAtIon
The aim of this study is to determine whether social 
vigilance may serve as a trigger for the pathway linking 
stress to atherosclerotic disease risk, and whether BP 
reactivity during daily life mediates this risk. We expect 
that greater social vigilance (ie, higher self-report and 
more frequent daily experience) will be associated 
with higher carotid IMT scores at each time point and 
predict faster rate of progression over time and that 
momentary BP reactivity will (at least in part) mediate 
these effects. This study is significant because it takes 
the critical next step of evaluating social vigilance as 
a predictor of objective disease. It will also provide 
evidence for the mechanistic pathways underlying the 
relationship. Identification of CVD-relevant biobe-
havioural pathways can inform targeted interventions 
to modify such behaviour.
One of the unique contributions afforded by the 
proposed design and methodology will be the ability 
to demonstrate the benefits of variation in sampling 
frequency of psychosocial factors in relation to physical 
health biomarkers and processes. As explained, three 
gradients of assessment of psychosocial constructs will 
be employed in this study—traditional survey measures, 
daily summary measures and EMA. This provides for 
convergent validity across time scales and methods, but 
also allows for the development and testing of multilevel 
and multisystem hypotheses, determining the unique and 
synergistic influences of social vigilance, and other oppor-
tunities that arise from this rich and layered data. For 
example, prior research in pain suggests that global self-re-
port measures and EMA are complementary approaches, 
each explaining unique variance in outcomes.67 68 More 
recent work has suggested that EMA data may be more 
sensitive than global retrospective reports in predicting 
health changes, including carotid IMT.35 69 70 Thus, we 
will be able to explore the predictive and clinical utility of 
social vigilance assessed at different levels and time scales 
and by using different methods.
The proposed study is also innovative in its approach to 
examining the biobehavioural pathway between psycho-
social constructs, such as vigilance, and physical health 
indicators, such as atherosclerosis. Whereas examination of 
blood-based biomarkers such as inflammation are routinely 
used to link psychosocial factors to atherosclerosis, we pair 
EMA with ABMP in addition to inflammatory markers. This 
sampling approach allows us to test hypotheses regarding 
acute physiological reactions to vigilance in daily life as a 
mediator of the stress-related progression in atherosclerosis 
with intervention implications.
lIMItAtIons
Despite our best efforts, we recognise that there are 
several challenges to the proposed study. First, it is 
possible that either the amount of measureable disease 
will be too low to detect in our sample or that insuf-
ficient change will occur within the 2-year follow-up 
to detect vigilance effects on progression. To address 
this possibility, we have chosen to have all participants 
undergo a complete bilateral duplex ultrasound to 
ascertain disease information including plaque forma-
tions and blood flow in all extracranial vessels. This 
approach essentially has a power effect commensurate 
with increasing the number of sampling data points. By 
imaging the entire vasculature, we increase the observa-
tional space in which to detect disease relative to more 
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focused investigations of specific vascular segments 
while maintaining our ability to examine those specific 
regions.
A second possibility is that vigilance may be more influ-
ential at different time points in the disease process. For 
example, social vigilance may generally produce mild 
to moderate cardiovascular reactions that are below 
threshold for disease development but may be detri-
mental in the context of existing disease. This possibility 
would require a completely different approach and 
involve examining the effects of vigilance in a clinical 
sample; we leave this for future studies.
A third possibility is that vigilant behaviour varies as 
a function of age and stage of life. For example, work-
ing-age individuals may be higher in social vigilance as 
a function of more frequent social interactions through 
work or school. Older individuals including retirees may 
engage in less vigilance as a result of advancing age, 
disease and reduced mobility effects on ability and desire 
to seek out social engagement. We intend to include age 
in our models, but it is possible that we are underpowered 
to detect significant, age-related cohort effects.
Finally, it is possible that despite conceptual distinc-
tions, social vigilance simply may not translate into unique 
disease impact. A strength of our approach is the inclusion 
of conceptually related variables and the ability to test this 
possibility. Although we expect that vigilance will emerge 
as a significant moderator of carotid IMT, the alternative 
outcome would also be an important contribution to the 
literature given the widespread hypothesising of vigilance 
effects on disease and the lack of objective data.
This study protocol is approved by the Institutional 
Review Board at the University of North Texas (coordi-
nating location) and will abide by all regulations aimed 
at valuing and preserving respect and safety in human 
factors research. Study findings will be disseminated in 
scientific journals and conferences.
conclusIon
We believe that this study represents an innovative and 
significant conceptual advance in understanding the 
relationship between social vigilance and atherosclerotic 
risk and a methodological demonstration of the bene-
fits of variations in candidate psychosocial risk factor 
sampling for testing relationships with physical health 
endpoints. This will be the first investigation to examine 
social vigilance as a determinant of objectively measured 
atherosclerosis in humans. Importantly, this evidence 
will be a necessary step in demonstrating that vigilance 
is distinct from other psychosocial risk factors, such as 
neuroticism and hostility, in that it is a basic downstream 
mechanism by which such individual differences influ-
ence CHD. Findings will improve understanding of the 
basic biobehavioural pathways linking social stress to 
CHD risk, demonstrate the methodological utility of 
varying sampling techniques and inform targeted inter-
ventions to ameliorate stress-related disease.
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